DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zanaflex (Tizanidine Hydrochloride) - Summary

 
 



ZANAFLEX SUMMARY

Zanaflex (tizanidine hydrochloride) is a centrally acting alpha2-adrenergic agonist.

Zanaflex (tizanidine) is indicated for the following:

Tizanidine is a short-acting drug for the management of spasticity. Because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see DOSAGE AND ADMINISTRATION).


See all Zanaflex indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Zanaflex (Tizanidine)

Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety. [2010]
spasticity requiring treatment... CONCLUSIONS: Overnight sublingual tizanidine provides improvement in next-day

Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. [2009]
Tizanidine and aceclofenac individually have shown efficacy in the treatment of low back pain... In this study, aceclofenac-tizanidine combination was more effective than aceclofenac alone and had a favourable safety profile in the treatment of acute low back pain.

Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. [2009]
compared... CONCLUSIONS: BoNT is safer and more effective than TZD in reducing tone and

Botulinum Neurotoxin vs Tizanidine in Upper Limb Spasticity: A Placebo-Controlled Study. [2008.10.31]
BACKGROUND: While spasticity is commonly treated with oral agents or botulinum neurotoxin (BoNT) injection, these treatments have not been systematically compared... CONCLUSIONS: BoNT is safer and more effective than TZD in reducing tone and disfigurement in upper extremity spasticity, and may be considered as first line therapy for this disorder.

Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. [2007.06]
Case reports suggest that cranberry juice can increase the anticoagulant effect of warfarin. We investigated the effects of cranberry juice on R-S-warfarin, tizanidine, and midazolam; probes of CYP2C9, CYP1A2, and CYP3A4.A pharmacokinetic mechanism for the cranberry juice-warfarin interaction seems unlikely.

more studies >>

Clinical Trials Related to Zanaflex (Tizanidine)

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies [Recruiting]
This open-label, multicenter, 3-period, fixed-sequence study will evaluate the e ffect of multiple oral doses of vemurafenib on the pharmacokinetics of a single oral dose of tizanidine in patients with BRAFV600 mutation-positive metastatic malignancies. Patients will receive a single oral dose of tizanidine on Day 1, v emurafenib orally twice daily on Days 2-21, and tizanidine and vemurafenib on Da y 22. Eligible patients will have the option to continue treatment with vemurafe nib as part of an extension study (NCT01739764).

One Year Extension Study To Protocol C2/5/TZ:MS-05 [Not yet recruiting]
Open label, one year extension study to evaluate the clinical efficacy and safety of 12 mg sublingual tizanidine administered once nightly in MS patients who successfully completed Phase I/II protocol C2/5/TZ: MS-05 at the Tel Aviv Sourasky Medical Center, Department of Neurology, Dr. Arnon Karni, PI.

Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164) [Not yet recruiting]
The primary objective of this study is to evaluate the safety and tolerability of MK-0663B (etoricoxib/tizanidine) among participants with moderate-to-severe acute low back pain.

Drug Discrimination in Methadone-Maintained Humans Study 3 [Recruiting]
This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the participant's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e. g., heart rate, blood pressure, respiration rate) and behavior. Each participant will receive 2-4 of the listed interventions.

Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury (SCI) [Recruiting]
The primary goal of the proposed clinical trial is to investigate the combined effects of walking training and monoaminergic agents (SSRIs and TIZ) on motor function of individuals in sub-acute (2-7 mo) human motor incomplete Spinal Cord Injury (SCI), with a primary emphasis on improvement in locomotor capability. We hypothesize that the use of these drugs applied early following SCI may facilitate independent stepping ability, and its combination with intensive stepping training will result in improved locomotor recovery following incomplete SCI. Loss of descending control via norepinephrine inputs following spinal cord injury can impair normal sensorimotor function through depressing motor excitability and impairing walking capacity. Replacing these inputs with drugs can alter the excitability and assist with reorganization of locomotor circuits. Assessment of single-dose administration of these agents has been tested in patients with motor incomplete spinal cord injury; only limited changes in walking performance have been noted. The resultant onset of weakness and increase in involuntary reflexes following motor incomplete SCI may partly be a result of damage to descending pathways to the spinal cord that control the release of serotonin. In models of SCI, for example, application of agents that simulate serotonin has been shown to change voluntary motor behaviors, including improvement of walking recovery. In humans following neurological injury, the effects of 5HT agents are unclear. Few previous reports indicate improved motor function following administration of agents which enhance the available serotonin in the brain, although some data suggests that increased serotonin may be beneficial. In this application, we propose to study the effects of clinically used agents that increase or decrease intrinsic serotonin activity in the brain on strength and walking ability following human motor incomplete SCI. Using detailed electrophysiological recordings, and biomechanical and behavioral measures, we will determine the effects of single or chronic doses of these drugs on voluntary and involuntary motor behaviors during clinical measures and walking measures. The novelty of this proposed research is the expectation that agents that increase serotonin activity may increase abnormal reflexes in SCI, but simultaneously help to facilitate motor and walking recovery. Despite potential improvements in voluntary function, the use of pharmacological agents that may enhance spastic motor behaviors following SCI is in marked contrast to the way in which drugs are typically used in the clinical setting.

more trials >>

Reports of Suspected Zanaflex (Tizanidine) Side Effects

Asthenia (17)Drug Ineffective (14)Blood Pressure Decreased (12)Fall (11)Multiple Sclerosis (10)Pneumonia (10)Cachexia (10)Death (5)Drug Interaction (4)Muscle Spasms (4)more >>


Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014